€56.00
-0.70 (-1.23%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VIS.MC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem CellsNCT06956807combination of MACCEs at all follow up visits during the first year after treatmentOpen-label · Treatment | Phase 1 | Not yet recruiting | Combination product: VB-C01 cellularised patch | CABG-patients, Heart Failure, Myocardial Infarction (MI) | 10 | 2026-12-31 | in 134 d | 2025-05-04 |
| First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular DysfunctionNCT03746938Composite safety endpoint formed by the major adverse cardiac and cerebrovascular events (MACCE) occurring on all visits during the first year after implantation.Open-label · Treatment | Phase 1 | Unknown status | Device: VB-C01 | Heart Failure With Reduced Ejection Fraction | 10 | 2020-10-30 | — | 2018-11-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19